Cantor Fitzgerald Upgrades Pacific Biosciences to Overweight, Lowers Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Ross Osborn has upgraded Pacific Biosciences (NASDAQ:PACB) from Neutral to Overweight and lowered the price target from $14 to $11.

October 31, 2023 | 2:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pacific Biosciences has been upgraded to Overweight from Neutral by Cantor Fitzgerald, but the price target has been lowered from $14 to $11.
The upgrade to Overweight indicates that the analyst believes the stock will outperform its peers in the future. However, the lowering of the price target suggests a downward revision of the company's future earnings potential. This could lead to mixed reactions in the market, but overall, the upgrade is likely to have a positive impact on the stock's performance in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100